Replies to post #127414 on NorthWest Biotherapeutics Inc (NWBO)

[abeta]

Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy.

CONCLUSION:
Autologous tumor lysate-pulsed DC vaccination in conjunction with TLR agonists is safe as adjuvant therapy in newly diagnosed and recurrent glioblastoma patients. Our results suggest that the mesenchymal gene expression profile may identify an immunogenic subgroup of glioblastoma that may be more responsive to immune-based therapies.

Prins and Liau

[abc1212]

abeta, based on the fact that we know how well Mesenchymal patients are doing, I was also interested to read the piece in Forbes that mentioned Epigenetic drugs

It said

Epigenetic drugs, which focus on flipping certain genes on or off (changing what the gene expresses) may hold promise

I may be barking up the wrong tree but what if there was another drug (as mentioned) that could switch off other gene expressions to end up with only Mesenchymal.

Then followed up with DCVax, well, I think that would speak for itself.

As I say, I may have this all wrong as not excactly sure what 'flipping genes on and off' accomplishes.

Any ideas?

Thanks